Remember that record biotech IPO party in 2018? There was no ‘happily ever after’
2023-05-08
IPO并购
Back in the summer of 2018, Aptinyx
$APTX
was budding with high hopes. Its predecessor company, Naurex, had sold to Allergan so Brent Saunders and his crew could advance their “breakthrough” NMDA drug to what looked like a promising drug worth $560 million. Aptinyx would take the rest forward through the clinic.
But over the last five years, that drug and everything that went to Aptinyx went up in multiple blasts of bad data, destroyed by a litany of setbacks and failures that would wipe out all evidence of its former promise. Allergan later would sell to AbbVie, primarily for its Botox franchise, after taking some nasty pipeline hits.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
-靶点
-药物
-热门报告
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。